Literature DB >> 22450194

Breast cancer: Aromatase inhibitors--bone health assessment is crucial.

Peyman Hadji.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22450194     DOI： 10.1038/nrclinonc.2012.47

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.

Authors:  Angela M Cheung; Lianne Tile; Savannah Cardew; Sandhya Pruthi; John Robbins; George Tomlinson; Moira K Kapral; Sundeep Khosla; Sharmila Majumdar; Marta Erlandson; Judy Scher; Hanxian Hu; Alice Demaras; Lavina Lickley; Louise Bordeleau; Christine Elser; James Ingle; Harriet Richardson; Paul E Goss
Journal:  Lancet Oncol       Date:  2012-02-07       Impact factor: 41.316

2.  Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.

Authors:  Edith A Perez; Robert G Josse; Kathleen I Pritchard; James N Ingle; Silvana Martino; Brian P Findlay; Tamara N Shenkier; Richard G Tozer; Michael J Palmer; Lois E Shepherd; Shifang Liu; Dongsheng Tu; Paul E Goss
Journal:  J Clin Oncol       Date:  2006-07-05       Impact factor: 44.544

3.  The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.

Authors:  Peyman Hadji; Lina Asmar; Johanna G H van Nes; Thomas Menschik; Annette Hasenburg; Joachim Kuck; Johan W R Nortier; Cornelis J H van de Velde; Stephen E Jones; May Ziller
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-18       Impact factor: 4.553

Review 4.  Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.

Authors:  P Hadji; M S Aapro; J J Body; N J Bundred; A Brufsky; R E Coleman; M Gnant; T Guise; A Lipton
Journal:  Ann Oncol       Date:  2011-03-17       Impact factor: 32.976

5.  Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Authors:  R C Coombes; L S Kilburn; C F Snowdon; R Paridaens; R E Coleman; S E Jones; J Jassem; C J H Van de Velde; T Delozier; I Alvarez; L Del Mastro; O Ortmann; K Diedrich; A S Coates; E Bajetta; S B Holmberg; D Dodwell; E Mickiewicz; J Andersen; P E Lønning; G Cocconi; J Forbes; M Castiglione; N Stuart; A Stewart; L J Fallowfield; G Bertelli; E Hall; R G Bogle; M Carpentieri; E Colajori; M Subar; E Ireland; J M Bliss
Journal:  Lancet       Date:  2007-02-17       Impact factor: 79.321

6.  Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.

Authors:  Cornelis J H van de Velde; Daniel Rea; Caroline Seynaeve; Hein Putter; Annette Hasenburg; Jean-Michel Vannetzel; Robert Paridaens; Christos Markopoulos; Yasuo Hozumi; Elysee T M Hille; Dirk G Kieback; Lina Asmar; Jan Smeets; Johan W R Nortier; Peyman Hadji; John M S Bartlett; Stephen E Jones
Journal:  Lancet       Date:  2011-01-22       Impact factor: 79.321

7.  Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).

Authors:  Richard Eastell; Rosemary A Hannon; Jack Cuzick; Mitch Dowsett; Glen Clack; Judith E Adams
Journal:  J Bone Miner Res       Date:  2006-08       Impact factor: 6.741

8.  The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.

Authors:  P Hadji; M Ziller; D G Kieback; T Menschik; M Kalder; J Kuck; A Hasenburg
Journal:  Breast       Date:  2009-04-11       Impact factor: 4.380

Review 9.  Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.

Authors:  Peyman Hadji
Journal:  Crit Rev Oncol Hematol       Date:  2008-08-30       Impact factor: 6.312

10.  Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.

Authors:  Paul E Goss; Peyman Hadji; Milayna Subar; Paula Abreu; Torben Thomsen; Jose Banke-Bochita
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466
  10 in total
  1 in total

1.  Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.

Authors:  Elizabeth Maunsell; Paul E Goss; Rowan T Chlebowski; James N Ingle; José E Alés-Martínez; Gloria E Sarto; Carol J Fabian; Pascal Pujol; Amparao Ruiz; Andrew L Cooke; Susan Hendrix; Debra W Thayer; Kendrith M Rowland; Pierre Dubé; Silvana Spadafora; Sandhya Pruthi; Lavina Lickley; Susan L Ellard; Angela M Cheung; Jean Wactawski-Wende; Karen A Gelmon; Dianne Johnston; Andrea Hiltz; Michael Brundage; Joseph L Pater; Dongsheng Tu; Harriet Richardson
Journal:  J Clin Oncol       Date:  2014-04-07       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.